A long-lasting injectable treatment for preventing organ transplant rejection
Long-acting injectable tacrolimus for chronic immunosuppression
This study is testing a new long-lasting injection of tacrolimus, a medicine that helps prevent organ rejection in transplant patients, so you won’t have to take daily pills and can maintain steady levels of the drug for a whole month after just one shot.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Auritec Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Pasadena, United States) |
| Project ID | NIH-10662560 on NIH RePORTER |
What this research studies
This research focuses on developing a long-acting injectable form of tacrolimus, a medication used to prevent organ rejection in transplant recipients. The new formulation aims to provide consistent therapeutic levels of the drug for 30 days after a single injection, addressing issues of medication adherence associated with daily oral dosing. By utilizing innovative technology, the study seeks to improve patient outcomes and reduce the risk of organ rejection due to fluctuating drug levels. Patients will be monitored for their response to this new treatment approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have undergone organ transplantation and require immunosuppressive therapy to prevent organ rejection.
Not a fit: Patients who are not organ transplant recipients or those who do not require immunosuppressive therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve medication adherence and graft survival rates in organ transplant recipients.
How similar studies have performed: Previous studies have shown success with long-acting injectable formulations in other therapeutic areas, suggesting potential for this novel approach in immunosuppression.
Where this research is happening
Pasadena, United States
- Auritec Pharmaceuticals, INC. — Pasadena, United States (Active)
Researchers
- Principal investigator: Smith, Thomas J. — Auritec Pharmaceuticals, INC.
- Study coordinator: Smith, Thomas J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.